Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07248144 phase 1/2a study in advanced solid tumors
jRCT2031200246Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Nov 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of prifetrastat in breast cancer, prostate cancer (PCa) and non-small cell lung cancer (NSCLC) (9 arms), sponsored by Pfizer. Primary endpoints: Number of participants with dose-limiting toxicities, Safety and tolerability by adverse event monitoring and 3 more. Started Nov 2020; status: recruiting.
02
Drugs
prifetrastat
03
Conditions
breast cancerprostate cancer (PCa)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031200246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200246.